41 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
by the Securities Act and the Public Company Accounting Oversight Board (United States). Marcum LLP has not been engaged by the Company to perform any
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable
424B5
ajnwvxmgfsb2fkvn
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
ttwzjeh5r54
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
xbz4 3mwml31
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
svi1934k
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
6y9e007 mcy9recze
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
nk47il jp4
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
p0xi9btnujey12aso3im
22 Oct 19
Prospectus supplement for primary offering
4:24pm